Picture of Trans Lux logo

TNLX — Trans Lux News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

Australia's Telix Pharma rises as candidate for bone marrow disease meets goals

** Drugmaker Telix Pharmaceuticals Ltd  TLX.AX  rises as
much as 11.25% to A$4.45, posts biggest intraday percentage gain
since Dec. 11
    ** Co says its bone marrow conditioning investigational
candidate TLX66 (90Y-besilesomab) has met study objectives in
Patients with AL Amyloidosis, a rare disease where plasma cells
in bone marrow produce abnormal protein which causes organs to
fail  urn:newsml:reuters.com:*:nFWN2NB0TW
    ** TLX says this TLX66 has potential to reduced toxicity
significantly and improve tolerability compared with existing
chemotherapeutic conditioning approaches
    ** Co says if a complete response is achieved patient can
live 10 yrs+
    ** Stock hits its highest level since April 7
    ** About 700,000 shares change hands compared to the 30-day
average volume of about 561,000 shares
    ** TLX down 5.8% this year, as of last close
       

 (Reporting by Aditya Munjuluru in Bengaluru)
 ((aditya.srivastsav@thomsonreuters.com))

Recent news on Trans Lux

See all news